Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus mycophenolate mofetil in childhood steroid-dependent nephrotic syndrome
2018-001042-33Phase 2Completed
- Sponsor
- Istituto Giannina Gaslini
- Start
- Oct 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in nephrosis comparing Ofatumumab with Mycophenolate mofetil (2 arms). Primary endpoint: Risk of relapse within 12 months without steroid administration. Started Oct 2018; status: completed.
02
Drugs
ofatumumabmycophenolate mofetil
03
Conditions
nephrosis
Beyond the preview
Go deeper on 2018-001042-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001042-33.